NCT00365339View on ClinicalTrials.gov

Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
HIV Infections
Interventions
DRUG

Atazanavir+Ritonavir+Tenofovir

Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.

DRUG

Atazanavir+Ritonavir+Tenofovir+Famotidine

Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.

DRUG

Atazanavir+Ritonavir+Tenofovir+Famotidine

Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.

DRUG

Atazanavir+Ritonavir+Tenofovir+Famotidine

Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.

DRUG

Atazanavir+Ritonavir+Tenofovir+Famotidine

Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.

Trial Locations (1)

Unknown

Local Institution, Hamilton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY